Oksvold, Morten P.
Berglund, Ulrika Warpman
Gad, Helge
Bai, Baoyan
Stokke, Trond
Rein, Idun Dale
Pham, Therese
Sanjiv, Kumar
Øy, Geir Frode
Norum, Jens Henrik
Smeland, Erlend B.
Myklebust, June H.
Helleday, Thomas
Våtsveen, Thea Kristin
Funding for this research was provided by:
Norges Forskningsråd
Kreftforeningen
European Research Council (ERC-2015-Adg_695376)
Barncancerfonden
Swedish Cancer Foundation
Helse Sør-Øst RHF
Article History
Received: 22 September 2020
Accepted: 23 February 2021
First Online: 18 March 2021
Competing interests
: A patent has been filed with TH588 and TH1579 where T.H. is listed as inventor. The Intellectual Property Right is owned by the non-profit Thomas Helleday Foundation for Medical Research (THF). T.H., U.W.B., K.S. and H.G. are board members of the THF. THF is sponsor for on-going clinical trial with TH1579. Oxcia AB is assisting THF in TH1579 clinical trial and U.W.B is chairman of Oxcia AB. H.G., U.W.B., T.P., K.S. and T.H. are shareholders in Oxcia AB. The other authors declare no competing interests.